Allergan Gets Positive Opinion For Its Truberzi For Irritable Bowel Syndrome With Diarrhoea Treatment In Adults

Allergan plc AGN revealed that the Committee for Medicinal Products for Human Use (CHMP) has adopted a favorable Opinion for its TRUBERZI in the European Union. According to the company, TRUBERZI is an oral medication, which get rid of the main symptoms of irritable bowel syndrome with diarrhoea (IBS-D) in adults.

Allergan said that in two pivotal studies, TRUBERZI has reduced considerably two of the most bothersome symptoms of IBS-D, i.e. abdominal pain and diarrhoea, with sustained relief demonstrated in six months. The company added that TRUBERZI was generally well tolerated with the most common side effects being nausea, constipation, and abdominal pain.

The drug maker's Chief R&D Officer, David Nicholson, commented, "With this positive decision for TRUBERZI®, Allergan is one step closer to bringing this innovative medication to IBS-D patients across Europe who are in desperate need of new treatment options."

He added, "Once approved, TRUBERZI® will join CONSTELLA® (linaclotide) as the only licensed prescription medications proven to treat bothersome symptoms of IBS-D and irritable bowel syndrome with constipation (IBS-C) respectively. Offering these effective treatment options to physicians and their patients underscores Allergan's commitment to helping address unmet needs in gastrointestinal diseases."

Allegan indicated that IBS is common in the globe, with an estimated prevalence of around 11 percent. The company pointed out that about one third of IBS patients were predicted to have IBS-D. The company also pointed out a pan-European survey, which expects that about 3.5 million people in western European countries have IBS-D.